This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

A Busy Week for Six Biotech Stocks

Stocks in this article: ACUR PTIE FCSC.OB CRIS BIIB RPC PFE

BOSTON ( TheStreet) -- Three drug approval decisions and a cancer drug data presentation highlight a busy week ahead in biotech.

Traders will be eyeing Acura Pharmaceuticals (ACUR) early Monday to see how the stock reacts following the U.S. approval of the company's tamper-resistant painkiller Oxecta on Friday night. Pfizer (PFE), Acura's marketing partner, will sell Oxecta in the U.S.

Acura shares closed Friday's regular session down 5% to $3.87 but is sure to rebound and move higher when trading opens Monday. How much so likely depends on the data and language FDA allowed in the Oxecta label describing the drug's tamper-resistant qualities.

Pain Therapeutics (PTIE) is expecting an FDA approval decision on Thurs. June 23 for its own tamper-resistant opioid, Remoxy, which is also being developed in a partnership with Pfizer.

Remoxy was first submitted for FDA approval three years ago so Pain Therapeutics shareholders are hoping this week brings a positive end to what's been a long wait. Pain Therapeutics shares closed Friday at $8.64 -- watch Monday to see if investors move the stock higher on bullish sentiment stemming from the approval of Acura's Oxecta.

Curis (CRIS) shares will be under a spotlight Monday on the release of data from a phase II study of vismodegib in basal cell carcinoma, a form of skin cancer.

The overall response rate in the study, assessed independently, showed vismodegib shrank tumors in 43% of patients with locally advanced basal cell carcinoma and 30% of patients with metastatic basal cell carcinoma. The median duration of response was 7.8 months, according to Curis. Patients in the phase II study had advanced basal cell carcinoma that was no longer responsive to any other therapy.

Roche is developing vismodegib under a partnership agreement with Curis and has already announced plans to seek U.S. approval later this year.

Switching back to FDA drug approvals this week, Fibrocell (FCSC.OB) awaits a June 22 decision on laViv, a personalized cell therapy for the treatment (smoothing out) of nasolabial fold wrinkles -- those are the skin folds that run from each side of the nose to the corners of the mouth.

What makes laViv different from Botox and the myriad of dermal fillers used commonly in cosmetic skin procedures today is its active ingredient -- a patient's own fibroblasts. These are a form of stem cell that matures into connective tissue fibers and help give skin strength and elasticity.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs